Impact of Switching to NNRTI-based Therapy on the Quality of Life of HIV-infected Patients With Virological Suppression

Observational Study of the Impact on Quality-of-life of a Switch From a Virologically Effective Regimen to a Regimen Containing a Non-Nucleoside Reverse Transcriptase Inhibitor (QUALVI) Nevirapine (Viramune®) Clinical Phase IV

Observational study to evaluate therapeutic switch to a NNRTI-based regimen on quality of life of HIV-positive patients

Inclusion Criteria:

• NNRTI-naive patients with positive HIV serology, treated with at least triple combination therapy, with a viral load < 500 copies/ml, in whom a new treatment comprising an NNRTI is initiated for a reason other than inefficacy of treatment will be included
• Patients must read and write French

Exclusion Criteria:

• Patients in whom a new treatment is initiated because of treatment failure
• new treatment does not comprise an NNRTI